<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; PowerShares Autonomic Gr NFA Glbl Asset</title>
	<atom:link href="http://www.stockbloghub.com/tag/powershares-autonomic-gr-nfa-glbl-asset/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BMY) Bristol-Myers Squibb&#8217;s Plavix Patent Getting Review</title>
		<link>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837</link>
		<comments>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837#comments</comments>
		<pubDate>Thu, 20 Aug 2009 17:57:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Glbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12837</guid>
		<description><![CDATA[Bristol-Myers Squibb (BMY) announced that its lead drug, Plavix, will be reviewed by the U.S. Patent and Trademark Office (PTO). Plavix is indicated for the reduction of the risk of heart attacks or strokes in patients with atherosclerosis (the build-up of plaque and hardening of the arteries). The drug is co-promoted with pharmaceutical giant Sanofi-Aventis (SNY). Plavix sales in the second quarter were $1,539 million, up 11%. Sales in 2008 were up 18% to $5.6 billion, making it one of the world’s best-selling pharmaceutical products. The patent of the antiplatelet blood thinner is expected to expire in November 2011, although the companies might win a six-month extension for conducting pediatric studies. Canada-based Apotex has requested the U.S. Patent and Trademark Office to review the patent as the company is looking to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

